In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria

Dalbavancin is a novel semisynthetic glycopeptide with enhanced activity against gram-positive species. Its comparative in vitro activities and those of nine comparator agents, including daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin, against 290 recent gram-positive clinical isolates strains, as determined by the NCCLS agar dilution method, were studied. The MICs of dallbavancin at which 90% of various isolates tested were inhibited were as follows: Actinomyces spp., 0.5 mug/ml; Clostridium clostridioforme, 8 mug/ml; C. difficile, 0.25 mug/ml; C. innocuum, 0.25 mug/ml; C. perfringens, 0.125 mug/ml; C. ramosum, 1 mug/ml; Eubacterium spp., 1 mug/ml; Lactobacillus spp., > 32 mug/ml, Propionibacterium spp., 0.5 mug/ml; and Peptostreptococcus spp., 0.25 mug/ml. Dalbavancin was 1 to 3 dilutions more active than vancomycin against most strains. Dalbavancin exhibited excellent activity against gram-positive strains tested and warrants clinical evaluation.